Aethlon Medical, Inc. (OTCMKTS:AEMD) Update On Hemopurifier Clinical Study Protocol

Aethlon Medical, Inc. (OTCMKTS:AEMD) said that the first subject enrolled in its FDA approved feasibility trial has completed full Hemopurifier treatment protocol. There are no device-related adverse events occurred during this time. The protocol is being under observation at DaVita Med Center Dialysis. The enrollment is done on ten chronic dialysis subjects infected with Hepatitis C virus. They will receive treatment protocol of company’s Hemopurifier therapy.

The study

The Aethlon Hemopurifier is a premium bio-filtration device that offers the wide-spectrum removal of infectious viruses from the circulatory system of patients. The trial will provide efficacy data to advance the device as a candidate treatment to cure chronic conditions such as HCV and HIV. Also, it will cure acute pandemic and bioterror threats that do not have proven vaccine or drug therapies. Aethlon updated the details of the trial, including patient enrollment and treatment protocol on its official website.

The management view

Jim Joyce, the CEO of Aethlon Medical, Inc. (OTCMKTS:AEMD), said that with the feasibility trial underway, the management will commence its previously announced plan to file HUD submissions. They offer a prospective FDA market clearance pathway to cure viral indications attacking fewer than 4,000 persons in the U.S. each year.

The use and significance

Aethlon’s Hemopurifier therapy has been used outside the the treatment of HIV, Ebola, and HCV-infected patients. The previous Vitro studies have shown that Hemopurifier identifies Ebola hemorrhagic virus, Lassa hemorrhagic virus, and dengue hemorrhagic virus. The others are H5N1 avian influenza, the reconstructed 1918 influenza virus, 2009 H1N1 influenza virus, West Nile virus, and monkeypox. The trials were done with leading non-government and government research firms including USAMRIID, CDC, The ‘National Institute of Virology’, BBRC and SFBR. Hemopurifier is the lead product of the Aethlon that selectively aims the rapid removal of circulating tumor-secreted exosomes and viruses that lead to cancer progression.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 All RIGHTS RESERVED.